Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

NCT04974216 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

71

Enrollment

OTHER

Sponsor class

Conditions

DLBCL

Interventions

DRUG: Tafasitamab
DRUG: Lenalidomide
DRUG: Rituximab

Sponsor

The Lymphoma Academic Research Organisation